This study revealed several roles for members of this family, including that SP140 is a pivotal prognostic biomarker in hematologic malignancies (e.g., hypomethylation in AML predicts favorable outcomes, while mutations in MCL drive aggressive disease). This evidence concerns the gene SP140 and acute myeloid leukemia.